Intra-umbilical vein injection and retained placenta: evidence from a collaborative large randomised controlled trial. Grupo Argentino de Estudio de Placenta Retenida. 1998

G Carroli, and J M Belizan, and A Grant, and L Gonzalez, and L Campodonico, and E Bergel
Centro Rosario de Estudios Perinatales, Rosario, Argentina.

OBJECTIVE To determine whether intra-umbilical vein injection with saline solution, with or without oxytocin, reduces the need for manual removal of placenta compared with expectant management. METHODS Multicenter, randomised controlled trial. METHODS Eleven hospitals in four cities of Argentina: Buenos Aires, Corrientes, Rosario, and Salta. METHODS Two hundred and ninety-one women showing no evidence of placental separation thirty minutes after vaginal delivery. METHODS Three different management strategies: 1. intra-umbilical vein injection of saline solution plus oxytocin; 2. intra-umbilical vein injection of saline solution alone; and 3. expectant management. METHODS Primary: manual removal of the placenta. Secondary: blood loss after trial entry, haemoglobin level at 24 to 48 hours and at 40 to 45 days after delivery, blood transfusion, curettage, infection, and days of hospital stay. RESULTS Rates of subsequent manual removal were similar: intra-umbilical vein injection of saline solution plus oxytocin (58%; RR 0.92; 95% CI 0.73-1.15), or saline alone (63%; RR 1.00; 95% CI 0.80-1.24), compared with expectant management (63%). There were also no detectable effects of the active managements on any of the secondary measures of outcome. CONCLUSIONS Based on evidence available from randomised controlled trials, including this trial, it is unlikely that intra-umbilical injection with or without oxytocin, is clinically useful. We recommend that this intervention should not be used in third stage management of labour.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D010121 Oxytocin A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION. Ocytocin,Pitocin,Syntocinon
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012965 Sodium Chloride A ubiquitous sodium salt that is commonly used to season food. Sodium Chloride, (22)Na,Sodium Chloride, (24)NaCl
D014471 Umbilical Veins Venous vessels in the umbilical cord. They carry oxygenated, nutrient-rich blood from the mother to the FETUS via the PLACENTA. In humans, there is normally one umbilical vein. Umbilical Vein,Vein, Umbilical,Veins, Umbilical
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D018457 Placenta, Retained A placenta that fails to be expelled after BIRTH of the FETUS. A PLACENTA is retained when the UTERUS fails to contract after the delivery of its content, or when the placenta is abnormally attached to the MYOMETRIUM. Retained Placenta,Placentas, Retained,Retained Placentas

Related Publications

G Carroli, and J M Belizan, and A Grant, and L Gonzalez, and L Campodonico, and E Bergel
January 2010, Lancet (London, England),
G Carroli, and J M Belizan, and A Grant, and L Gonzalez, and L Campodonico, and E Bergel
May 2011, The Cochrane database of systematic reviews,
G Carroli, and J M Belizan, and A Grant, and L Gonzalez, and L Campodonico, and E Bergel
January 2001, The Cochrane database of systematic reviews,
G Carroli, and J M Belizan, and A Grant, and L Gonzalez, and L Campodonico, and E Bergel
January 2000, The Cochrane database of systematic reviews,
G Carroli, and J M Belizan, and A Grant, and L Gonzalez, and L Campodonico, and E Bergel
March 2021, The Cochrane database of systematic reviews,
G Carroli, and J M Belizan, and A Grant, and L Gonzalez, and L Campodonico, and E Bergel
April 1991, British journal of obstetrics and gynaecology,
G Carroli, and J M Belizan, and A Grant, and L Gonzalez, and L Campodonico, and E Bergel
January 2010, Lancet (London, England),
G Carroli, and J M Belizan, and A Grant, and L Gonzalez, and L Campodonico, and E Bergel
October 2005, BJOG : an international journal of obstetrics and gynaecology,
G Carroli, and J M Belizan, and A Grant, and L Gonzalez, and L Campodonico, and E Bergel
October 2019, Sexual & reproductive healthcare : official journal of the Swedish Association of Midwives,
G Carroli, and J M Belizan, and A Grant, and L Gonzalez, and L Campodonico, and E Bergel
January 2014, Archives of gynecology and obstetrics,
Copied contents to your clipboard!